Art

J-GLOBAL ID：201602246298647247   Reference number：16A1175885

Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation

ゲムシタビンは,CD20上方制御によるB細胞リンパ腫に対するリツキシマブ媒介補体依存性細胞毒性を高める

Author (8)： Hayashi Kazumi (Division of Oncology, The Jikei University School of Medicine, Tokyo, Japan) ,  Hayashi Kazumi (Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan) ,  Nagasaki Eijiro (Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan) ,  Kan Shin (Division of Oncology, The Jikei University School of Medicine, Tokyo, Japan) ,  Ito Masaki (Division of Oncology, The Jikei University School of Medicine, Tokyo, Japan) ,  Kamata Yuko (Division of Oncology, The Jikei University School of Medicine, Tokyo, Japan) ,  Homma Sadamu (Division of Oncology, The Jikei University School of Medicine, Tokyo, Japan) ,  Aiba Keisuke (Division of Oncology, The Jikei University School of Medicine, Tokyo, Japan)
Material： Cancer Science (Web)  (Cancer Sci (Web))
Volume： 107  Issue： 5  Page： 682-689  Publication year： 2016 
JST Material Number： U0505A  ISSN： 1349-7006  Document type： Article
Article type： 原著論文  Country of issue： United States (USA)  Language： ENGLISH (EN)

Thesaurus term： CD20 antigen ,...
Semi thesaurus term： Rituximab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=16A1175885&from=J-GLOBAL&jstjournalNo=U0505A") }}

Author keywords (5)： CD20 ,  complement dependent cytotoxicity ,  diffuse B cell lymphoma ,  gemcitabine ,  rituximab

JST classification (3)： Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Basic oncology in general  (GE02010R) ,  Blood cell tumors(=neoplasms)  (GK04000M)

Substance index (1)： Gemcitabine

Reference (42)：

• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-95.
• Pettengell R, Linch D; Haemato-Oncology Task Force of the British Committee for Standards in Haematology. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. Br J Haematol 2003; 121: 44-8.
• Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-33.
• Ardeshna KM, Qian W, Smith P et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 2014; 15: 424-35.
• Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-74.

Terms in the title (8)： ゲムシタビン ,  CD20 ,  上方制御 ,  B細胞リンパ腫 ,  リツキシマブ ,  補体 ,  依存性 ,  細胞毒性